TITLE

ABLYNX AND GENENCOR FORM ONCOLOGY COLLABORATION

PUB. DATE
November 2004
SOURCE
Worldwide Biotech;Nov2004, Vol. 16 Issue 11, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the oncology drug discovery collaboration of Ablynx and Genencor International. Information on the technology that will be used in the partnership; Terms of the partnership; Role of each company in the discovery and development of a new drug against tumor; Profiles of Ablynx and Genencor.
ACCESSION #
14884350

 

Related Articles

  • Genencor to Partner With Cargill Dow on Biomass.  // Chemical Market Reporter;9/15/2003, Vol. 264 Issue 8, p3 

    Reports on the partnership of Genencor International Inc. and Cargill Dow LLC to develop enzyme systems to convert biomass into lactic acid in the U.S. Disclosure of the financial terms of the alliance; Provision of feedstock for Cargill Dow's polylactide operations; Development of...

  • Alliances Update.  // PharmaWatch: Biotechnology;Dec2006, Vol. 5 Issue 12, p14 

    The article offers international news briefs related to strategic alliances of biopharmaceutical firms. The Debiopharm Group and Cambridge Antibody Technology Group PLC have entered a licensing agreement to develop SC-1 for gastric cancer from SC-1 technology. Wyeth Laboratories Inc. and Ablynx...

  • NOx Levels Mar Ozone Effort. Franz, Neil // Chemical Week;10/31/2001, Vol. 163 Issue 40, p41 

    Presents updates that are related to ozone emission in the United States as of October 31, 2001. Increase in ozone levels; Other chemical emissions which have declined; Alliance between Dow Corning and Genencor International to use silicon biotechnology in products.

  • Alliances, partnerships improve printing options.  // Frontline Solutions;Feb2001, Vol. 2 Issue 2, p46 

    Focuses on several alliances, partnerships among thermal printer manufacturers. Marketing alliance between Datamax and scanner manufacturer Hand Held Products; Partnership between Zebra Technologies and warehouse management system provider Catalyst International.

  • COMPOST AND "GREEN-TAGGED" ELECTRICITY FROM REGIONAL PARTNERSHIP.  // BioCycle;Sep2003, Vol. 44 Issue 9, p19 

    Reports on the creation of the Snohomish Basin Biogas Partnership in Marysville, Washington. Names of organizations taking part in the formation of the alliance; Purpose of the partnership; Comments made on the significance of pooling together organizations with same interests.

  • Wilex Stock Rises on UCB Oncology Alliance. Sheridan, Cormac // BioWorld Today;1/12/2009, Vol. 20 Issue 6, p4 

    The article reports that news of a strategic alliance between Wilex AG and UCB SA, which is worth 10 million up front and another possible 10 million in two near-term milestones, has caused Wilex AG's shares to gain as much as 42 percent. Wilex is taking on responsibility for developing UCB's...

  • Merck and Vertex collaborate to develop and commercialize cancer compound.  // PharmaWatch: Biotechnology;August 2004, Vol. 3 Issue 8, p16 

    Shares in pharmaceutical company Vertex Inc. were up 8 percent after it confirmed that it had entered into a global collaboration with Merck & Co. Inc. to develop and commercialize its VX- 680 cancer inhibitor. Under the terms of the agreement, Vertex will receive a $20 million upfront payment...

  • Cell Genesys and Novartis enter global strategic alliance for oncolytic virus therapy products.  // PharmaWatch: Cancer;September 2003, Vol. 2 Issue 9, p17 

    Reports that the drug firms Cell Genesys and Novartis AG started a global alliance for the development of oncolytic virus therapies. Cell Genesys' acquisition of rights to intellectual property held by Genetic Therapy, an affiliate of Novartis; Cell Genesys' issuance of stocks to Novartis.

  • Quintiles and Eisai partner to develop oncology products.  // PharmaWatch: Cancer;Dec2009, Vol. 8 Issue 12, p16 

    The article presents information on the strategic alliance between Quintiles Transnational Corp. and Eisai Co. Ltd. The collaboration aims to develop new oncology drugs and is structured on risk-sharing basis. Quintiles will partly fund the design and conduct of the clinical studies and will...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics